Adipose tissue lipolysis as a metabolic pathway to define pharmacological strategies against obesity and the metabolic syndrome

Pharmacological Research

Volumn 53, Issue 6, 2006, Pages 482-491

  Langin, Dominique ^a,b  

^a INSERM   (France)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Adipose tissue; Fat mobilization; Lipolysis; Metabolic syndrome; Obesity

Indexed keywords

4 ISOPROPYL 3 METHYL 2 [1 (3 METHYL PIPERIDIN 1 YL) METHANOYL] 2H ISOXAZOL 5 ONE; ADENOSINE A1 RECEPTOR AGONIST; ADRENOMEDULLIN; ALPHA 2 ADRENERGIC RECEPTOR; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR; CATECHOLAMINE DERIVATIVE; HORMONE SENSITIVE LIPASE; ISOXAZOLE DERIVATIVE; NATRIURETIC FACTOR; NEUROPEPTIDE; NICOTINIC ACID; NITRIC OXIDE; PERILIPIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADIPOCYTE; ADIPOSE TISSUE; EXPERIMENTAL MODEL; FLUSHING; HORMONE ACTION; HUMAN; HYPERLIPIDEMIA; LIPID METABOLISM; LIPID TRANSPORT; LIPOLYSIS; METABOLIC SYNDROME X; NONHUMAN; OBESITY; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; SIDE EFFECT;

ADIPOSE TISSUE; GTP-BINDING PROTEIN ALPHA SUBUNITS, GI-GO; HUMANS; LIPASE; LIPOLYSIS; METABOLIC SYNDROME X; NATRIURETIC PEPTIDES; OBESITY; RECEPTORS, ADRENERGIC, ALPHA-2; RECEPTORS, ADRENERGIC, BETA; SIGNAL TRANSDUCTION; TRIGLYCERIDES;

EID: 33646778517     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2006.03.009     Document Type: Review

References (104)

1. Mauriège P., Pergola G.D., Berlan M., and Lafontan M. Human fat cell beta-adrenergic receptors: beta agonist-dependent lipolytic responses and characterization of beta-adrenergic binding sites on human fat cell membranes with highly selective beta1-antagonists. J Lipid Res 29 (1988) 587-601
2. Barbe P., Millet L., Galitzky J., Lafontan M., and Berlan M. In situ assessment of the role of the β1-, β2- and β3-adrenoceptors in the control of lipolysis and nutritive blood flow in human subcutaneous adipose tissue. Br J Pharmacol 117 (1996) 907-913
3. Lowell B.B., and Bachman E.S. Beta-adrenergic receptors, diet-induced thermogenesis, and obesity. J Biol Chem 278 (2003) 29385-29388
4. Arch J.R.S., and Wilson S. Prospects for β3-adrenoceptor agonists in the treatment of obesity and diabetes. Int J Obes 20 (1996) 191-199
5. Tavernier G., Barbe P., Galitzky J., Berlan M., Caput D., Lafontan M., et al. Expression of β3-adrenoceptors with low lipolytic action in human subcutaneous fat cells. J Lipid Res 37 (1996) 87-97
6. Langin D., Portillo M.P., Saulnier-Blache J.S., and Lafontan M. Coexistence of three beta-adrenoceptor subtypes in white fat cells of various mammalian species. Eur J Pharmacol 199 (1991) 291-301
7. Galitzky J., Langin D., Verwaerde P., Montastruc J.-L., Lafontan M., and Berlan M. Lipolytic effects of conventional β3-adrenoceptor agonists and of CGP 12,177 in rat and human fat cells: preliminary pharmacological evidence for a putative β4-adrenoceptor. Br J Pharmacol 122 (1997) 1244-1250
8. Galitzky J., Langin D., Montastruc J.-L., Lafontan M., and Berlan M. On the presence of a putative fourth beta-adrenoceptor in human adipose tissue. Trends Pharmacol Sci 19 (1998) 164-166
9. Konkar A., Zhai Y., and Granneman J. β1-adrenergic receptors mediate β3-adrenergic-independent effects of CGP12177 in brown adipose tissue. Mol Pharmacol 57 (2000) 252-258
10. Weyer C., Tataranni P.A., Snitker S., Danforth E., and Ravussin E. Increase in insulin action and fat oxidation after treatment with CL 316,243, a highly selective β3-adrenoceptor agonist in humans. Diabetes 47 (1998) 1555-1561
11. Schiffelers S.L.H., Blaak E.E., Saris W.H.M., and Baak M.A.V. In vivo β3-adrenergic stimulation of human thermogenesis and lipid utilization. Clin Pharmacol Ther 67 (2000) 558-566
12. Tavernier G., Gimenez M., Giacobino J.P., Hulo N., Lafontan M., Muzzin P., et al. Norepinephrine induces lipolysis in β1/β2/β3-adrenoceptor knockout mice. Mol Pharmacol 68 (2005) 793-799
13. Lafontan M., and Berlan M. Fat cell α2-adrenoceptors: the regulation of fat cell function and lipolysis. Endocrine Rev 16 (1995) 716-738
14. Stich V., De Glisezinski I., Suljkovicova H., Crampes F., Galitzky J., Rivière D., et al. Activation of antilipolytic α2-adrenergic receptors by epinephrine during exercise in human adipose tissue. Am J Physiol 277 (1999) R1076-R1083
15. Stich V., De Glisezinski I., Crampes F., Hejnova J., Cottet-Emard J.-M., Galitzky J., et al. Activation of α2-adrenergic receptors impairs exercise-induced lipolysis in SCAT of obese subjects. Am J Physiol 279 (2000) 499-504
16. Berlan M., Montastruc J.-L., and Lafontan M. Pharmacological prospects for α2-adrenoceptor antagonist therapy. Trends Pharmacol Sci 13 (1992) 277-282
17. Sengenès C., Berlan M., De Glisezinski I., Lafontan M., and Galitzky J. Natriuretic peptides: a new lipolytic pathway in human adipocytes. FASEB J 14 (2000) 1345-1351
18. Sengenes C., Zakaroff-Girard A., Moulin A., Berlan M., Bouloumie A., Lafontan M., et al. Natriuretic peptide-dependent lipolysis in fat cells is a primate specificity. Am J Physiol Regul Integr Comp Physiol 283 (2002) R257-R265
19. Sengenes C., Bouloumie A., Hauner H., Berlan M., Busse R., Lafontan M., et al. Involvement of a cGMP-dependent pathway in the natriuretic peptide-mediated hormone-sensitive lipase phosphorylation in human adipocytes. J Biol Chem 278 (2003) 48617-48626
20. Galitzky J., Sengenes C., Thalamas C., Marques M.A., Senard J.M., Lafontan M., et al. The lipid-mobilizing effect of atrial natriuretic peptide is unrelated to sympathetic nervous system activation or obesity in young men. J Lipid Res 42 (2001) 536-544
21. Moro C., Galitzky J., Sengenes C., Crampes F., Lafontan M., and Berlan M. Functional and pharmacological characterization of the natriuretic peptide-dependent lipolytic pathway in human fat cells. J Pharmacol Exp Ther 308 (2004) 984-992
22. Moro C., Crampes F., Sengenes C., De Glisezinski I., Galitzky J., Thalamas C., et al. Atrial natriuretic peptide contributes to physiological control of lipid mobilization in humans. FASEB J 18 (2004) 908-910
23. Birkenfeld A.L., Boschmann M., Moro C., Adams F., Heusser K., Franke G., et al. Lipid mobilization with physiological atrial natriuretic peptide concentrations in humans. J Clin Endocrinol Metab 90 (2005) 3622-3628
24. Colucci W.S., Elkayam U., Horton D.P., Abraham W.T., Bourge R.C., Johnson A.D., et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med 343 (2000) 246-253
25. Abassi Z., Karram T., Ellaham S., Winaver J., and Hoffman A. Implications of the natriuretic peptide system in the pathogenesis of heart failure: diagnostic and therapeutic importance. Pharmacol Ther 102 (2004) 223-241
26. Gravholt C.H., Schmitz O., Simonsen L., Bulow J., Christiansen J.S., and Moller N. Effects of a physiological GH pulse on interstitial glycerol in abdominal and femoral adipose tissue. Am J Physiol 277 (1999) E848-E854
27. Samra J.S., Clark M.L., Humphreys S.M., Macdonald I.A., Bannister P.A., Matthews D.R., et al. Suppression of the nocturnal rise in growth hormone reduces subsequent lipolysis in subcutaneous adipose tissue. Eur J Clin Invest 29 (1999) 1045-1052
28. Heffernan M.A., Jiang W.J., Thorburn A.W., and Ng F.M. Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism. Am J Physiol 279 (2000) E501-E507
29. Heffernan M.A., Thorburn A.W., Fam B., Summers R., Conway-Campbell B., Waters M.J., et al. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int J Obes Relat Metab Disord 25 (2001) 1442-1449
30. Hauner H., Petruschke T., Russ M., Röhrig K., and Eckel J. Effects of tumor necrosis factor alpha (TNFα) on glucose transport and lipid metabolism of newly differentiated human fat cells in culture. Diabetologia 38 (1995) 764-771
31. Souza S.C., Vargas L.Md., Yamamoto M.T., Lien P., Franciosa M.D., Moss L.G., et al. Overexpression of perilipin A and B blocks the ability of tumor necrosis factor-α to increase lipolysis in 3T3-L1 adipocytes. J Biol Chem 273 (1998) 24665-24669
32. Gasic S., Tian B., and Green A. Tumor necrosis factor alpha stimulates lipolysis in adipocytes by decreasing Gi protein concentrations. J Biol Chem 274 (1999) 6770-6775
33. Rahn Landstrom T., Mei J., Karlsson M., Manganiello V., and Degerman E. Down-regulation of cyclic-nucleotide phosphodiesterase 3B in 3T3-L1 adipocytes induced by tumour necrosis factor alpha and cAMP. Biochem J 346 (2000) 337-343
34. Mei J., Holst L.S., Landstrom T.R., Holm C., Brindley D., Manganiello V., et al. C2-ceramide influences the expression and insulin-mediated regulation of cyclic nucleotide phosphodiesterase 3B and lipolysis in 3T3-L1 adipocytes. Diabetes 51 (2002) 631-637
35. Ryden M., Dicker A., Harmelen V.V., Hauner H., Brunnberg M., Perbeck L., et al. Mapping of early signalling events in TNFα-mediated lipolysis in human fat cells. J Biol Chem 277 (2002) 1085-1091
36. Marcus C., Ehrén H., Bolme P., and Arner P. Regulation of lipolysis during the neonatal period. Importance of thyrotropin. J Clin Invest 82 (1988) 1793-1797
37. Sinha T.K., Thajchayapong P., Queener S.F., Allen D.O., and Bell N.H. On the lipolytic action of parathyroid hormone in man. Metabolism 25 (1976) 251-260
38. Akesson L., Ahren B., Manganiello V.C., Holst L.S., Edgren G., and Degerman E. Dual effects of pituitary adenylate cyclase-activating polypeptide and isoproterenol on lipid metabolism and signaling in primary rat adipocytes. Endocrinology 144 (2003) 5293-5299
39. Akesson L., Ahren B., Edgren G., and Degerman E. VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes. Endocrinology 146 (2005) 744-750
40. Bing C., Bao Y., Jenkins J., Sanders P., Manieri M., Cinti S., et al. Zinc-alpha2-glycoprotein, a lipid mobilizing factor, is expressed in adipocytes and is up-regulated in mice with cancer cachexia. Proc Natl Acad Sci USA 101 (2004) 2500-2505
41. Gaudiot N., Jaubert A.-M., Charbonnier E., Sabourault D., Lacasa D., Giudicelli Y., et al. Modulation of white adipose tissue lipolysis by nitric oxide. J Biol Chem 273 (1998) 13475-13481
42. Andersson K., Gaudiot N., Ribière C., Elizalde M., Giudicelli Y., and Arner P. A nitric oxide-mediated mechanism regulates lipolysis in human adipose tissue in vivo. Br J Pharmacol 126 (1999) 1639-1645
43. Karpe F., and Frayn K.N. The nicotinic acid receptor-a new mechanism for an old drug. Lancet 363 (2004) 1892-1894
44. Tunaru S., Kero J., Schaub A., Wufka C., Blaukat A., Pfeffer K., et al. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med 9 (2003) 352-355
45. Wise A., Foord S.M., Fraser N.J., Barnes A.A., Elshourbagy N., Eilert M., et al. Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem 278 (2003) 9869-9874
46. Zhang Y., Schmidt R.J., Foxworthy P., Emkey R., Oler J.K., Large T.H., et al. Niacin mediates lipolysis in adipose tissue through its G-protein coupled receptor HM74A. Biochem Biophys Res Commun 334 (2005) 729-732
47. Taggart A.K., Kero J., Gan X., Cai T.Q., Cheng K., Ippolito M., et al. d-beta-Hydroxybutyrate inhibits adipocyte lipolysis via the nicotinic acid receptor PUMA-G. J Biol Chem 280 (2005) 26649-26652
48. Chatzipanteli K., Rudolph S., and Axelrod L. Coordinate control of lipolysis by prostaglandin E2 and prostacyclin in rat adipose tissue. Diabetes 41 (1992) 927-935
49. Borglum J.D., Pedersen S.B., Ailhaud G., Negrel R., and Richelsen B. Differential expression of prostaglandin receptor mRNAs during adipose cell differentiation. Prostaglandins Other Lipid Mediat 57 (1999) 305-317
50. Kather H. Purine accumulation in human fat cell suspensions. J Biol Chem 263 (1988) 8803-8809
51. Kather H. Pathways of purine metabolism in human adipocytes: further evidence against a role of adenosine as an endogenous regulator of human fat cell function. J Clin Invest 265 (1990) 96-102
52. Lönnroth P., Jansson P.-A., Fredholm B.B., and Smith U. Microdialysis of intercellular adenosine concentration in subcutaneous adipose tissue in humans. Am J Physiol 256 (1989) E250-E255
53. Schoelch C., Kuhlmann J., Gossel M., Mueller G., Neumann-Haefelin C., Belz U., et al. Characterization of adenosine-A1 receptor-mediated antilipolysis in rats by tissue microdialysis, 1H-spectroscopy, and glucose clamp studies. Diabetes 53 (2004) 1920-1926
54. Valet P., Berlan M., Beauville M., Crampes F., Montastruc J.-L., and Lafontan M. Neuropeptide Y and peptide YY inhibit lipolysis in human and dog fat cells through a pertussis toxin-sensitive G protein. J Clin Invest 85 (1990) 291-295
55. Castan I., Valet P., Voisin T., Quideau N., Laburthe M., and Lafontan M. Identification and functional studies of a specific peptide YY-preferring receptor in dog adipocytes. Endocrinology 131 (1992) 1970-1976
56. Castan I., Valet P., Larrouy D., Voisin T., Remaury A., Daviaud D., et al. Distribution of PYY receptors in human fat cells: an antilipolytic system alongside the alpha2-adrenergic one. Am J Physiol 265 (1993) E74-E80
57. Serradeil-Le Gal C., Lafontan M., Raufaste D., Marchand J., Pouzet B., Casellas P., et al. Characterization of NPY receptors controlling lipolysis and leptin secretion in human adipocytes. FEBS Lett 475 (2000) 150-156
58. Turtzo L.C., Marx R., and Lane M.D. Cross-talk between sympathetic neurons and adipocytes in coculture. PNAS 98 (2001) 12385-12390
59. Frayn K.N. Adipose tissue as a buffer for daily lipid flux. Diabetologia 45 (2002) 1201-1210
60. Degerman E., Landstrom T.R., Wijkander J., Holst L.S., Ahmad F., Belfrage P., et al. Phosphorylation and activation of hormone-sensitive adipocyte phosphodiesterase Type 3B. Methods 14 (1998) 43-53
61. Wijkander J., Landstrom T.R., Manganiello V., Belfrage P., and Degerman E. Insulin-induced phosphorylation and activation of phosphodiesterase 3B in rat adipocytes, possible role for protein kinase B but not mitogen-activated protein kinase or p70 S6 kinase. Endocrinology 139 (1998) 219-227
62. Harmancey R., Senard J.M., Pathak A., Desmoulin F., Claparols C., Rouet P., et al. The vasoactive peptide adrenomedullin is secreted by adipocytes and inhibits lipolysis through NO-mediated beta-adrenergic agonist oxidation. FASEB J 19 (2005) 1045-1047
63. Sullivan J.E., Brocklehurst K.J., Marley A.E., Carey F., Carling D., and Beri R.K. Inhibition of lipolysis and lipogenesis in isolated rat adipocytes with AICAR, a cell-permeable activator of AMP-activated protein kinase. FEBS Lett 353 (1994) 33-36
64. Daval M., Diot-Dupuy F., Bazin R., Hainault I., Viollet B., Vaulont S., et al. Anti-lipolytic action of AMP-activated protein kinase in rodent adipocytes. J Biol Chem 280 (2005) 25250-25257
65. Garton A.J., Campbell D.G., Carling D., Hardie D.G., Colbran R.J., and Yeaman S.J. Phosphorylation of bovine hormone-sensitive lipase by the AMP-activated protein kinase. A possible antilipolytic mechanism. Eur J Biochem 179 (1989) 249-254
66. Ruderman N., and Prentki M. AMP kinase and malonyl-Coa: targets for therapy of the metabolic syndrome. Nat Rev Drug Discov 3 (2004) 340-351
67. Osuga J., Ishibashi S., Oka T., Yagyu H., Tozawa R., Fujimoto A., et al. Targeted disruption of hormone-sensitive lipase results in male sterility and adipocyte hypertrophy, but not in obesity. Proc Natl Acad Sci USA 97 (2000) 787-792
68. Haemmerle G., Zimmermann R., Strauss J.G., Kratky D., Riederer M., Knipping G., et al. Hormone-sensitive lipase deficiency in mice changes the plasma lipid profile by affecting the tissue-specific expression pattern of lipoprotein lipase in adipose tissue and muscle. J Biol Chem 277 (2002) 12946-12952
69. Mulder H., Sorhede-Winzell M., Contreras J.A., Fex M., Strom K., Ploug T., et al. Hormone-sensitive lipase null mice exhibit signs of impaired insulin sensitivity whereas insulin secretion is intact. J Biol Chem 278 (2003) 36380-36388
70. Harada K., Shen W.-J., Patel S., Natu V., Wang J., Osuga J.-I., et al. Resistance to high-fat diet-induced obesity and altered expression of adipose-specific genes in HSL-deficient mice. Am J Physiol Endocrinol Metab 285 (2003) E1182-E1195
71. Zimmermann R., Strauss J.G., Haemmerle G., Schoiswohl G., Birner-Gruenberger R., Riederer M., et al. Fat mobilization in adipose tissue is promoted by adipose triglyceride lipase. Science 306 (2004) 1383-1386
72. Jenkins C.M., Mancuso D.J., Yan W., Sims H.F., Gibson B., and Gross R.W. Identification, cloning, expression, and purification of three novel human calcium-independent phospholipase A2 family members possessing triacylglycerol lipase and acylglycerol transacylase activities. J Biol Chem 279 (2004) 48968-48975
73. Villena J.A., Roy S., Sarkadi-Nagy E., Kim K.-H., and Sul H.S. Desnutrin, an adipocyte gene encoding a novel patatin domain-containing protein, is induced by fasting and glucocorticoids: ectopic expression of desnutrin increases triglyceride hydrolysis. J Biol Chem 279 (2004) 47066-47075
74. Langin D, Dicker A, Tavernier G, Hoffstedt J, Mairal A, Ryden M, et al. Adipocyte lipases and defect of lipolysis in human obesity. Diabetes 2005;54(11):3190-7.
75. Fredrikson G., Strålfors P., Nilsson N.O., and Belfrage P. Hormone-sensitive lipase of rat adipose tissue. Purification and some properties. J Biol Chem 256 (1981) 6311-6320
76. Haemmerle G., Zimmermann R., Hayn M., Theussl C., Waeg G., Wagner E., et al. Hormone-sensitive lipase deficiency in mice causes diglyceride accumulation in adipose tissue, muscle, and testis. J Biol Chem 277 (2002) 4806-4815
77. Fredrikson G., Tornqvist H., and Belfrage P. Hormone-sensitive lipase and monoacylglycerol lipase are both required for complete degradation of adipocyte triacylglycerol. Biochim Biophys Acta 876 (1986) 288-293
78. Belfrage P., Fredrikson G., Strålfors P., and Tornquist H. Adipose tissue lipases. In: Borgström B., and Brockman H. (Eds). Lipases (1984), Elsevier, Amsterdam, The Netherlands 366-416
79. Langin D., Lucas S., and Lafontan M. Millenium fat cell lipolysis reveals unsuspected novel tracks. Horm Metab Res 32 (2000) 443-452
80. Strålfors P., Björgell P., and Belfrage P. Hormonal regulation of hormone-sensitive lipase in intact adipocytes: identification of phosphorylated sites and effects on the phosphorylation by lipolytic hormones and insulin. Proc Natl Acad Sci USA 81 (1984) 3317-3321
81. Egan J.J., Greenberg A.S., Chang M.-K., Wek S.A., MC Moos J., and Londos C. Mechanism of hormone-stimulated lipolysis in adipocytes: translocation of hormone-sensitive lipase to the lipid storage droplet. Proc Natl Acad Sci USA 89 (1992) 8537-8541
82. Soni K.G., Lehner R., Metalnikov P., O'Donnell P., Semache M., Gao W., et al. Carboxylesterase 3 (EC 3.1.1.1) is a major adipocyte lipase. J Biol Chem 279 (2004) 40683-40689
83. Slee D.H., Bhat A.S., Nguyen T.N., Kish M., Lundeen K., Newman M.J., et al. Pyrrolopyrazinedione-based inhibitors of human hormone-sensitive lipase. J Med Chem 46 (2003) 1120-1122
84. Lowe D.B., Magnuson S., Qi N., Campbell A.-M., Cook J., Hong Z., et al. In vitro SAR of (5-(2H)-isoxazolonyl) ureas, potent inhibitors of hormone-sensitive lipase. Bioorg Med Chem Lett 14 (2004) 3155-3159
85. Ebdrup S., Sorensen L.G., Olsen O.H., and Jacobsen P. Synthesis and structure-activity relationship for a novel class of potent and selective carbamoyl-triazole based inhibitors of hormone sensitive lipase. J Med Chem 47 (2004) 400-410
86. de Jong J.C., Sorensen L.G., Tornqvist H., and Jacobsen P. Carbazates as potent inhibitors of hormone-sensitive lipase. Bioorg Med Chem Lett 14 (2004) 1741-1744
87. Contreras J.A., Karlsson M., Østerlund T., Laurell H., Svensson A., and Holm C. Hormone-sensitive lipase is structurally related to acetylcholinesterase, bile salt-stimulated lipase, and several fungal lipases. Building of a three-dimensional model for the catalytic domain of hormone-sensitive lipase. J Biol Chem 271 (1996) 31426-31430
88. Shen W.-J., Sridhar K., Bernlohr D.A., and Kraemer F.B. Interaction of rat hormone-sensitive lipase with adipocyte lipid-binding protein. Proc Natl Acad Sci USA 96 (1999) 5528-5532
89. Smith A.J., Sanders M.A., Thompson B.R., Londos C., Kraemer F.B., and Bernlohr D.A. Physical association between the adipocyte fatty acid-binding protein and hormone-sensitive lipase: a fluorescence resonance energy transfer analysis. J Biol Chem 279 (2004) 52399-52405
90. Coe N.R., Simpson M.A., and Bernlohr D.A. Targeted disruption of the adipocyte lipid-binding protein (aP2 protein) gene impairs fat cell lipolysis and increases cellular fatty acid levels. J Lipid Res 40 (1999) 967-972
91. Scheja L., Makowski L., Uysal K.T., Wiesbrock S.M., Shimshek D.R., Meyers D.S., et al. Altered insulin secretion associated with reduced lipolytic efficiency in aP2-/- mice. Diabetes 48 (1999) 1987-1994
92. Baar R.A., Dingfelder C.S., Smith L.A., Bernlohr D.A., Wu C., Lange A.J., et al. Investigation of in vivo fatty acid metabolism in AFABP/aP2(-/-) mice. Am J Physiol Endocrinol Metab 288 (2005) E187-E193
93. Syu L.J., and Saltiel A.R. Lipotransin: a novel docking protein for hormone-sensitive lipase. Mol Cell 4 (1999) 109-115
94. Londos C., Sztalryd C., Tansey J.T., and Kimmel A.R. Role of PAT proteins in lipid metabolism. Biochimie 87 (2005) 45-49
95. Martinez-Botas J., Anderson J.B., Tessier D., Lapillonne A., Chang B.H., Quast M.J., et al. Absence of perilipin results in leanness and reverses obesity in Leprdb/db mice. Nat Genet 26 (2000) 474-479
96. Tansey J.T., Sztalryd C., Gruia-Gray J., Roush D.L., Zee J.V., Gavrilova O., et al. Perilipin ablation results in a lean mouse with aberrant adipocyte lipolysis, enhanced leptin production, and resistance to diet-induced obesity. PNAS 98 (2001) 6494-6499
97. Sztalryd C., Xu G., Dorward H., Tansey J.T., Contreras J.A., Kimmel A.R., et al. Perilipin A is essential for the translocation of hormone-sensitive lipase during lipolytic activation. J Cell Biol 161 (2003) 1093-1103
98. Brasaemle D.L., Dolios G., Shapiro L., and Wang R. Proteomic analysis of proteins associated with lipid droplets of basal and lipolytically stimulated 3T3-L1 adipocytes. J Biol Chem 279 (2004) 46835-46842
99. Hamilton J.A., and Kamp F. How are free fatty acids transported in membranes? Is it by proteins or by free diffusion through the lipids?. Diabetes 48 (1999) 2255-2269
100. Maeda N., Funahashi T., Hibuse T., Nagasawa A., Kishida K., Kuriyama H., et al. Adaptation to fasting by glycerol transport through aquaporin 7 in adipose tissue. Proc Natl Acad Sci USA 101 (2004) 17801-17806
101. Hara-Chikuma M., Sohara E., Rai T., Ikawa M., Okabe M., Sasaki S., et al. Progressive adipocyte hypertrophy in aquaporin-7-deficient mice: adipocyte glycerol permeability as a novel regulator of fat accumulation. J Biol Chem 280 (2005) 15493-15496
102. Hibuse T., Maeda N., Funahashi T., Yamamoto K., Nagasawa A., Mizunoya W., et al. Aquaporin 7 deficiency is associated with development of obesity through activation of adipose glycerol kinase. Proc Natl Acad Sci USA 102 (2005) 10993-10998
103. Nisoli E., and Carruba M.O. Emerging aspects of pharmacotherapy for obesity and metabolic syndrome. Pharmacol Res 50 (2004) 453-469
104. Tiraby C., and Langin D. Conversion of white into brown adipocytes: a strategy for the control of fat mass?. Trends Endocrinol Metab 14 (2003) 439-441